Browse the corpus

REFERENCES Basu A, Ramkumar M, Tan HP, et al, “Reversal of Acute Cellular Rejection After Renal Transplantation With Campath-1H,” Transplant Proc , 2005, 37(2):923-6. [PubMed 15848576 ] Berger JR and Houff S, “Opportunistic Infections and Other Risks With Newer Multiple Sclerosis Therapies,” Ann Neurol , 2009, 65(4):367-77. [PubMed 19399841 ] CAMMS223 Trial Investigators: Coles AJ, Compston DA, Selmaj KW, et al, “Alemtuzumab vs Interferon Beta-1a in Early Multiple \Sclerosis,” N Engl J Med , 2008, 359(17):1786-801. [PubMed 18946064 ] Ciancio G, Burke GW, Gaynor JJ, et al, “A Randomized Trial of Three Renal Transplant Induction Antibodies: Early Comparison of Tacrolimus, Mycophenolate Mofetil, and Steroid Dosing, and Newer Immune-Monitoring,” Transplantation , 2005, 80(4):457-65. [PubMed 16123718 ] Coles AJ, Fox E, Vladic A, et al, “Alemtuzumab More Effective Than Interferon Β-1a at 5-Year Follow-Up of CAMMS223 Clinical Trial,” Neurology, 2012, 78(14):1069-78. [PubMed 22442431 ] Cuker A, Coles AJ, Sullivan H, et al, “A Distinctive Form of Immune Thrombocytopenia in a Phase 2 Study of Alemtuzumab for the Treatment of Relapsing-Remitting Multiple Sclerosis,” Blood , 2011, 118(24):6299-305. [PubMed 21960587 ] Dearden CE, Johnson R, Pettengell R, et al, “Guidelines for the Management of Mature T-Cell and NK-Cell Neoplasms (Excluding Cutaneous T-Cell Lymphoma),” Br J Haematol , 2011, 153(4):451-85. [PubMed 21480860 ] Dearden CE, Matutes E, Cazin B, et al, “High Remission Rate in T-Cell Prolymphocytic Leukemia With CAMPATH-1H,” Blood , 2001, 98(6):1721-6. [PubMed 11535503 ] Enblad G, Hagberg H, Erlanson M, et al, “A Pilot Study of Alemtuzumab (Anti-CD52 Monoclonal Antibody) Therapy for Patients With Relapsed or Chemotherapy-Refractory Peripheral T-cell Lymphomas,” Blood , 2003, 103(8):2920-4. [PubMed 15070664 ] Farney A, Sundberg A, Moore P, et al, “A Randomized Trial of Alemtuzumab vs Anti-Thymocyte Globulin Induction in Renal and Pancreas Transplantation,” Clin Transplant , 2008, 22(1):41-9. [PubMed 18217904 ] Ferrajoli A, O'Brien SM, Cortes JE, et al, “Phase II Study of Alemtuzumab in Chronic Lymphoproliferative Disorders,” Cancer , 2003, 98(4):773-8. [PubMed 12910522 ]

Farney A, Sundberg A, Moore P, et al, “A Randomized Trial of Alemtuzumab vs Anti-Thymocyte Globulin Induction in Renal and Pancreas Transplantation,” Clin Transplant , 2008, 22(1):41-9. [PubMed 18217904 ] Ferrajoli A, O'Brien SM, Cortes JE, et al, “Phase II Study of Alemtuzumab in Chronic Lymphoproliferative Disorders,” Cancer , 2003, 98(4):773-8. [PubMed 12910522 ] Hale G, Rebello P, Brettman LR, et al, “Blood Concentrations of Alemtuzumab and Antiglobulin Responses in Patients With Chronic Lymphocytic Leukemia Following Intravenous or Subcutaneous Routes of Administration, Blood , 2004, 104(4):948-55. [PubMed 15090452 ] Hamnvik OP, Larsen PR, and Marqusee E, “Thyroid Dysfunction From Antineoplastic Agents,” J Natl Cancer Inst , 2011, 103(21):1572-87. [PubMed 22010182 ] Hanaway MJ, Woodle ES, Mulgaonkar S, et al, “Alemtuzumab Induction In Renal Transplantation,” N Engl J Med , 2011, 364(20):1909-19. [PubMed 21591943 ] Hillmen P, Skotnicki A, Robak T, et al, “Alemtuzumab Compared With Chlorambucil as First-Line Therapy for Chronic Lymphocytic Leukemia,” J Clin Oncol , 2007, 25(35):5616-23. [PubMed 17984186 ] Kanda J, Lopez RD, and Rizzieri DA, "Alemtuzumab for the Prevention and Treatment of Graft-Versus-Host Disease," Int J Hematol , 2011, 93(5):586-93. [PubMed 21369856 ] Karlsson C, Hansson L, Celsing F, et al, “Treatment of Severe Refractory Autoimmune Hemolytic Anemia in B-Cell Chronic Lymphocytic Leukemia With Alemtuzumab (Humanized CD52 Monoclonal Antibody),” Leukemia , 2007, 21(3):511-4. [PubMed 17215854 ] Keating MJ, Cazin B, Coutré S, et al, “Campath-1H Treatment of T-Cell Prolymphocytic Leukemia in Patients for Whom at Least One Prior Chemotherapy Regimen Has Failed,” J Clin Oncol , 2002, 20(1):205-13. [PubMed 11773171 ] Keating MJ, Flinn I, Jain V, et al, “Therapeutic Role of Alemtuzumab (Campath-1H) in Patients Who Have Failed Fludarabine: Results of a Large International Study,” Blood , 2002, 99(10):3554-61. [PubMed 11986207 ] Kennedy B and Hillmen P, “Immunological Effects and Safe Administration of Alemtuzumab (MabCampath) in Advanced B-cLL,” Med Oncol , 2002, 19(Suppl):49-55. Lepretre S, Aurran T, Mahé B, et al, “Excess Mortality After Treatment With Fludarabine and Cyclophosphamide in Combination With Alemtuzumab in Previously Untreated Patients With Chronic Lymphocytic Leukemia in a Randomized Phase 3 Trial," Blood , 2012, 119(22):5104-10. [PubMed 22337714 ]

Kennedy B and Hillmen P, “Immunological Effects and Safe Administration of Alemtuzumab (MabCampath) in Advanced B-cLL,” Med Oncol , 2002, 19(Suppl):49-55. Lepretre S, Aurran T, Mahé B, et al, “Excess Mortality After Treatment With Fludarabine and Cyclophosphamide in Combination With Alemtuzumab in Previously Untreated Patients With Chronic Lymphocytic Leukemia in a Randomized Phase 3 Trial," Blood , 2012, 119(22):5104-10. [PubMed 22337714 ] Lundin J, Hagberg H, Repp R, et al, “Phase 2 Study of Alemtuzumab (Anti-CD52 Monoclonal Antibody) in Patients With Advanced Mycosis Fungoides/Sézary Syndrome,” Blood , 2003, 101(11):4267-72. [PubMed 12543862 ] Lundin J, Kimby E, Bjorkholm M, et al, “Phase II Trial of Subcutaneous Anti-CD52 Monoclonal Antibody Alemtuzumab (Campath-1H) as First-Line Treatment for Patients With B-Cell Chronic Lymphocytic Leukemia (B-CLL),” Blood , 2002, 100(3):768-73. [PubMed 12130484 ] Lundin J, Osterborg A, Brittinger G, et al, “CAMPATH-1H Monoclonal Antibody in Therapy for Previously Treated Low-Grade Non-Hodgkin's Lymphomas: A Phase II Multicenter Study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma,” J Clin Oncol , 1998, 16(10):3257-63. [PubMed 9779699 ] Magliocca JF and Knechtle SJ, “The Evolving Role of Alemtuzumab (Campath-1H) for Immunosuppressive Therapy in Organ Transplantation,” Transpl Int , 2006, 19(9):705-14. [PubMed 16918530 ] Marcos A, Eghtesad B, Fung JJ, et al, “Use of Alemtuzumab and Tacrolimus Monotherapy for Cadaveric Liver Transplantation: With Particular Reference to Hepatitis C Virus,” Transplantation , 2004, 78(7):966-71. [PubMed 15480160 ] Margreiter R, Klempnauer J, Neuhaus P, et al, “Alemtuzumab (Campath-1H) and Tacrolimus Monotherapy After Renal Transplantation: Results of a Prospective Randomized Trial,” Am J Transplant , 2008, 8(7):1480-5. [PubMed 18510632 ] Martinez C, Solano C, Ferrá C, et al, “Alemtuzumab as Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease: Results From a Phase II Study,” Biol Blood Marrow Transplant , 2009, 15(5):639-42. [PubMed 19361757 ] Mead AJ, Thomson KJ, Morris EC, et al, “HLA-Mismatched Unrelated Donors are a Viable Alternate Graft Source for Allogeneic Transplantation Following Alemtuzumab-Based Reduced-Intensity Conditioning,” Blood , 2010, 115(25):5147-53. [PubMed 20371745 ]

Martinez C, Solano C, Ferrá C, et al, “Alemtuzumab as Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease: Results From a Phase II Study,” Biol Blood Marrow Transplant , 2009, 15(5):639-42. [PubMed 19361757 ] Mead AJ, Thomson KJ, Morris EC, et al, “HLA-Mismatched Unrelated Donors are a Viable Alternate Graft Source for Allogeneic Transplantation Following Alemtuzumab-Based Reduced-Intensity Conditioning,” Blood , 2010, 115(25):5147-53. [PubMed 20371745 ] Osterborg A, Dyer MJ, Bunjes D, et al, “Phase II Multicenter Study of Human CD52 Antibody in Previously Treated Chronic Lymphocytic Leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia,” J Clin Oncol , 1997, 15(4):1567-74. [PubMed 9193354 ] Osterborg A, Fassas AS, Anagnostopoulos A, et al, “Humanifed CD52 Monoclonal Antibody Campath-1H as First-Line Treatment in Chronic Lymphocytic Leukaemia,” Br J Haematol , 1996, 93(1):151-3. [PubMed 8611450 ] Osterborg A, Karlsson C, and Lundin J, “Alemtuzumab to Treat Refractory Autoimmune Hemolytic Anemia or Thrombocytopenia in Chronic Lymphocytic Leukemia,” Curr Hematol Malig Rep , 2009, 4(1):47-53. [PubMed 20425438 ] Pawson R, Dyer MJ, Barge R, et al, “Treatment of T-Cell Prolymphocytic Leukemia With Human CD52 Antibody,” J Clin Oncol , 1997, 15(7):2667-72. [PubMed 9215839 ] Rai KR, Freter CE, Mercier RJ, et al, “Alemtuzumab in Previously Treated Chronic Lymphocytic Leukemia Patients Who Also Had Received Fludarabine,” J Clin Oncol , 2002, 20(18):3891-7. [PubMed 12228210 ] Scheinberg P, Nunez O, Weinstein B, et al, “Activity of Alemtuzumab Monotherapy in Treatment-Naive, Relapsed, and Refractory Severe Acquired Aplastic Anemia,” Blood , 2012, 119(2):345-54. [PubMed 22067384 ] Schnitzler M, Hasskerl J, Egger M, et al, “Successful Treatment of Severe Acute Intestinal Graft-Versus-Host Resistant to Systemic and Topical Steroids With Alemtuzumab,” Biol Blood Marrow Transplant , 2009, 15(8):910-18. [PubMed 19589480 ] Schweighofer CD, Ritgen M, Eichhorst BF, et al, “Consolidation With Alemtuzumab Improves Progression-Free Survival in Patients With Chronic Lymphocytic Leukaemia (CLL) in First Remission: Long-Term Follow-Up of a Randomized Phase III Trial of the German CLL Study Group (GCLLSG),” Br J Haematol , 2009, 144(1):95-8. [PubMed 19016732 ]

Schweighofer CD, Ritgen M, Eichhorst BF, et al, “Consolidation With Alemtuzumab Improves Progression-Free Survival in Patients With Chronic Lymphocytic Leukaemia (CLL) in First Remission: Long-Term Follow-Up of a Randomized Phase III Trial of the German CLL Study Group (GCLLSG),” Br J Haematol , 2009, 144(1):95-8. [PubMed 19016732 ] Stilgenbauer S, Zenz T, Winkler D, et al, “Subcutaneous Alemtuzumab in Fludarabine-Refractory Chronic Lymphocytic Leukemia: Clinical Results and Prognostic Marker Analyses from the CLL2H Study of the German Chronic Lymphocytic Leukemia Study Group,” J Clin Oncol , 2009, 27(24):3994-4001. [PubMed 19597025 ] Treon SP, Soumerai JD, Hunter ZR, et al, “Long-Term Follow-Up of Symptomatic Patients With Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia Treated With the Anti-CD52 Monoclonal Antibody Alemtuzumab,” Blood , 2011, 118(2):276-81. [PubMed 21566092 ] van Besien K, Artz A, Smith S, et al, “Fludarabine, Melphalan, and Alemtuzumab Conditioning in Adults With Standard-Risk Advanced Acute Myeloid Leukemia and Myelodysplastic Syndrome,” J Clin Oncol , 2005, 23(24):5728-38. [PubMed 16009946 ] van Besien K, Kunavakkam R, Rondon G, et al, “Fludarabine-Melphalan Conditioning for AML and MDS: Alemtuzumab Reduces Acute and Chronic GVHD Without Affecting Long-term Outcomes,” Biol Blood Marrow Transplant , 2009, 15(5):610-7. [PubMed 19361753 ] Vo AA, Wechsler EA, Wang J, et al, “Analysis of Subcutaneous (SQ) Alemtuzumab Induction Therapy in Highly Sensitized Patients Desensitized With IVIG and Rituximab,” Am J Transplant , 2008, 8(1):144-9. [PubMed 17973966 ] Willis F, Marsh JC, Bevan DH, et al, “The Effect of Treatment With Campath-1H in Patients With Autoimmune Cytopenias,” Br J Haematol , 2001, 114(4):891-8. [PubMed 11564082 ] Wolff D, Schleuning M, von Harsdorf S, et al, “Consensus Conference on Clinical Practice in Chronic GVHD: Second-Line Treatment of Chronic Graft-Versus-Host Disease,” Biol Blood Marrow Transplant , 2011, 17(1):1-17. [PubMed 20685255 ] Topic 8725 Version 45.0 © 2013 UpToDate, Inc. All rights reserved. | Subscription and License Agreement | Release: 21.6- C21.56 Licensed to: AsanBook Dig. Med. Lib. | Support Tag: [0505-109.224.62.197-C12E3FDE9F-S244013.14]